Five Prime Doses First Patient With Investigational Antibody FPA150
News
The Phase 1 clinical trial testing FPA150, an investigational antibody targeting the B7-H4 protein, in patients with solid tumors has dosed its first participant, Five Prime Therapeutics announced. Patients eligible for the ... Read more